You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Citation Tools

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Conlon K, Watson DC, Waldmann TA, et al
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
Journal for ImmunoTherapy of Cancer 2021;9:e003388. doi: 10.1136/jitc-2021-003388